Form D · Pharmaceuticals
Agile Sciences, Inc
Raleigh, NC · CIK 0001419641
Offering snapshot reported May 29, 2020 · SEC filing
- Reported sold
- $1M Offering amount: $5M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 18, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 29, 2020 | Initial | $1,000,000 | No comparison | 1 | SEC filing |
| Jun 11, 2010 | Amendment | $1,308,642 | No comparison | 8 | SEC filing |
| Nov 23, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-367898
Source: Form D, filed May 29, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Stephen Brand | Executive |
| John Cavanagh | Director |
| Bill Culpepper | Director |
| Harry Garland | Director |
| David La Vance | Director |
| Christian Melander | Director |
| Keith Stoneback | Director |
| Malcolm Thomas | Director, Executive |
| Steven Young | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
1791 Varsity Drive, Suite 150
Raleigh, NC, 27606
Raleigh, NC, 27606